Core Scientific (CORZZ) Financials

$6.63 +0.08 (+1.16%)

As of 04/17/2025 04:00 PM Eastern

Annual Income Statements for Core Scientific

This table shows Core Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-18	47	-2,146	-246	-1,315
Consolidated Net Income / (Loss)	-12	47	-2,146	-246	-1,315
Net Income / (Loss) Continuing Operations	-18	47	-2,146	-246	-1,315
Total Pre-Tax Income	-12	63	-2,163	-246	-1,314
Total Operating Income	-6.33	131	-2,110	8.96	-19
Total Gross Profit	9.39	239	8.40	123	121
Total Revenue	54	544	640	502	511
Operating Revenue	54	544	640	502	511
Total Cost of Revenue	51	306	632	379	390
Operating Cost of Revenue	51	306	632	379	390
Total Operating Expenses	16	107	2,118	114	140
Selling, General & Admin Expense	15	60	213	94	110
Marketing Expense	1.77	4.06	13	7.02	9.97
Research & Development Expense	5.27	7.67	27	7.18	12
Other Operating Expenses / (Income)	-	0.00	0.00	0.03	3.81
Impairment Charge	0.00	37	1,881	4.41	0.00
Other Special Charges / (Income)	-5.88	-2.06	-16	1.96	4.21
Total Other Income / (Expense), net	-5.88	-68	-54	-255	-1,295
Interest Expense	1.33	8.02	0.29	-20	0.49
Interest & Investment Income	-4.44	-44	-97	-86	-37
Other Income / (Expense), net	-0.11	-16	43	-189	-1,257
Income Tax Expense	0.00	16	-17	0.68	0.86
Basic Earnings per Share	($0.14)	$0.23	($6.30)	($0.65)	($4.39)
Weighted Average Basic Shares Outstanding	157.60M	207.26M	340.65M	379.86M	255.83M
Diluted Earnings per Share	($0.14)	$0.20	($6.30)	($0.65)	($4.39)
Weighted Average Diluted Shares Outstanding	157.60M	233.31M	340.65M	379.86M	255.83M
Weighted Average Basic & Diluted Shares Outstanding	-	0.00	373.80M	177.60M	294.12M

This table shows Core Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-435	-435	-0.39	-9.26	-41	-196	211	-805	-455	-266
Consolidated Net Income / (Loss)	-435	-435	-0.39	-9.26	-41	-196	211	-805	-455	-266
Net Income / (Loss) Continuing Operations	-435	-435	-0.39	-9.26	-41	-196	211	-805	-455	-266
Total Pre-Tax Income	-424	-456	-0.28	-9.13	-41	-195	211	-805	-455	-265
Total Operating Income	-401	-636	7.60	9.47	-12	3.93	55	6.58	-41	-40
Total Gross Profit	-27	-47	32	37	15	39	78	39	-0.16	4.76
Total Revenue	163	121	121	127	113	142	180	141	95	94
Operating Revenue	163	121	121	127	113	142	180	141	95	94
Total Cost of Revenue	190	168	89	90	97	103	102	102	96	90
Operating Cost of Revenue	190	168	89	90	97	103	102	102	96	90
Total Operating Expenses	374	589	24	27	27	35	23	32	41	44
Selling, General & Admin Expense	43	39	22	24	24	24	14	26	34	36
Marketing Expense	0.04	1.06	1.01	1.08	1.04	3.89	0.98	2.97	3.15	2.87
Research & Development Expense	6.19	2.66	1.42	1.64	2.25	1.88	1.80	2.17	2.84	5.02
Other Operating Expenses / (Income)	-	-	0.00	0.00	0.00	0.03	2.22	1.12	0.21	0.26
Other Special Charges / (Income)	-11	-4.32	-1.06	-0.76	-0.02	3.80	3.82	-0.27	0.51	0.15
Total Other Income / (Expense), net	-23	180	-7.89	-19	-29	-199	156	-811	-414	-225
Interest & Investment Income	-26	-22	-0.16	0.04	-2.20	-84	-14	-15	-7.07	-1.14
Other Income / (Expense), net	3.17	202	-28	-19	-27	-114	170	-796	-407	-224
Income Tax Expense	11	-21	0.10	0.13	0.11	0.34	0.21	0.14	0.13	0.38
Basic Earnings per Share	($1.23)	($1.06)	$0.00	($0.02)	($0.11)	($0.52)	$0.91	($4.51)	($1.17)	$0.38
Weighted Average Basic Shares Outstanding	354.20M	340.65M	375.42M	375.78M	382.48M	379.86M	230.95M	178.51M	292.49M	255.83M
Diluted Earnings per Share	($1.23)	($1.06)	$0.00	($0.02)	($0.11)	($0.52)	$0.78	($4.51)	($1.17)	$0.51
Weighted Average Diluted Shares Outstanding	354.20M	340.65M	375.42M	375.78M	382.48M	379.86M	282.53M	178.51M	292.49M	255.83M
Weighted Average Basic & Diluted Shares Outstanding	374.53M	373.80M	376.57M	382.61M	386.02M	177.60M	177.78M	258.22M	279.25M	294.12M

This table details how cash moves in and out of Core Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	1.81	123	-79	17	767
Net Cash From Operating Activities	-24	-57	205	65	43
Net Cash From Continuing Operating Activities	-24	-57	205	65	43
Net Income / (Loss) Continuing Operations	-12	47	-2,146	-246	-1,315
Consolidated Net Income / (Loss)	-12	47	-2,146	-246	-1,315
Depreciation Expense	9.40	33	225	96	113
Amortization Expense	1.30	1.37	7.97	1.19	11
Non-Cash Adjustments To Reconcile Net Income	4.95	-75	2,058	47	1,264
Changes in Operating Assets and Liabilities, net	-27	-64	60	167	-30
Net Cash From Investing Activities	-15	-424	-591	-3.00	-95
Net Cash From Continuing Investing Activities	-15	-425	-591	-3.00	-95
Purchase of Property, Plant & Equipment	0.00	0.00	-384	-17	-95
Sale of Property, Plant & Equipment	-	0.00	0.00	14	0.00
Divestitures	-	-	11	0.00	0.00
Other Investing Activities, net	-1.48	-59	-218	0.00	0.00
Net Cash From Financing Activities	41	604	306	-45	820
Net Cash From Continuing Financing Activities	41	604	306	-45	820
Repayment of Debt	-7.10	-49	-113	-45	-315
Repurchase of Common Equity	0.00	-	-32	0.00	0.00
Issuance of Debt	45	671	261	0.00	1,078
Issuance of Common Equity	-	-	0.00	0.00	55
Other Financing Activities, net	2.64	-18	190	0.00	1.50
Cash Interest Paid	2.90	38	86	4.71	29
Cash Income Taxes Paid	0.00	9.62	5.76	-0.37	-0.16

This table details how cash moves in and out of Core Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-103	15	17	7.47	-13	5.77	45	-17	157	583
Net Cash From Operating Activities	-52	116	20	18	5.43	22	22	1.20	5.71	14
Net Cash From Continuing Operating Activities	-52	116	20	18	5.43	22	22	1.20	5.71	14
Net Income / (Loss) Continuing Operations	-435	-435	-0.39	-9.26	-41	-196	211	-805	-455	-266
Consolidated Net Income / (Loss)	-435	-435	-0.39	-9.26	-41	-196	211	-805	-455	-266
Depreciation Expense	65	69	20	20	24	31	29	29	29	26
Amortization Expense	2.57	1.37	0.20	0.27	0.23	0.49	1.43	2.45	2.29	4.51
Non-Cash Adjustments To Reconcile Net Income	390	356	-7.76	14	15	26	-199	807	431	225
Changes in Operating Assets and Liabilities, net	-74	124	7.81	-7.58	7.52	159	-20	-33	-1.46	24
Net Cash From Investing Activities	-5.66	-139	-1.87	-0.62	-2.87	2.36	-32	-3.18	-31	-29
Net Cash From Continuing Investing Activities	-5.66	-139	-1.87	-0.62	-2.87	2.36	-32	-3.18	-31	-29
Purchase of Property, Plant & Equipment	-5.22	-140	-1.54	-0.95	-2.87	-12	-32	-3.14	-31	-29
Other Investing Activities, net	-0.44	0.75	-0.33	0.33	-	-	-0.08	-0.05	-0.07	0.19
Net Cash From Financing Activities	-45	38	-1.02	-9.95	-15	-18	54	-15	182	598
Net Cash From Continuing Financing Activities	-45	38	-1.02	-9.95	-15	-18	54	-15	182	598
Repayment of Debt	-78	14	-1.02	-9.95	-12	-22	-17	-11	-271	-15
Issuance of Debt	-0.08	45	0.00	-	-	-	20	-	448	610
Other Financing Activities, net	231	11	0.00	-	-3.41	3.41	-3.38	-4.10	6.01	2.97
Cash Interest Paid	24	16	0.32	0.43	0.77	3.20	2.81	15	8.10	2.62
Cash Income Taxes Paid	-7.32	6.54	-0.30	-0.04	-	-0.03	-0.00	-1.29	-	1.13

This table presents Core Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Total Assets	0.02	2,439	808	712	1,599
Total Current Assets	0.00	757	85	97	904
Cash & Equivalents	0.00	118	16	50	836
Restricted Cash	-	14	36	19	0.78
Accounts Receivable	-	1.68	0.26	1.00	1.03
Other Current Assets	-	593	0.72	26	66
Plant, Property, & Equipment, net	0.00	0.00	691	585	556
Total Noncurrent Assets	0.02	1,682	31	30	139
Other Noncurrent Operating Assets	0.02	618	30	30	139
Total Liabilities & Shareholders' Equity	0.02	2,439	808	712	1,599
Total Liabilities	0.00	1,053	1,217	1,309	2,419
Total Current Liabilities	0.00	320	187	488	135
Short-Term Debt	-	104	36	124	16
Accounts Payable	0.00	12	54	155	19
Accrued Expenses	0.00	68	18	180	69
Current Deferred Revenue	-	136	78	9.83	18
Other Current Liabilities	-	0.00	0.77	20	12
Total Noncurrent Liabilities	0.00	733	1,030	821	2,284
Long-Term Debt	-	652	0.00	684	1,074
Capital Lease Obligations	-	62	0.72	37	98
Other Noncurrent Operating Liabilities	0.00	19	1,030	99	1,113
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	0.01	1,341	-409	-597	-820
Total Preferred & Common Equity	0.01	1,341	-409	-597	-820
Preferred Stock	0.00	-	-	0.00	0.00
Total Common Equity	0.01	1,341	-409	-597	-820
Common Stock	0.03	1,380	1,764	1,823	2,915
Retained Earnings	-0.01	-27	-2,174	-2,420	-3,735

This table presents Core Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,404	760	751	705	814	761	922
Total Current Assets	214	100	111	135	143	118	278
Cash & Equivalents	30	47	58	42	98	96	253
Restricted Cash	8.10	22	19	22	16	0.98	0.78
Accounts Receivable	3.07	0.18	1.26	1.11	1.11	4.68	6.24
Other Current Assets	173	31	33	34	28	16	18
Plant, Property, & Equipment, net	1,156	628	608	547	576	550	550
Total Noncurrent Assets	34	32	32	23	95	94	94
Other Noncurrent Operating Assets	33	30	29	21	93	94	94
Total Liabilities & Shareholders' Equity	1,404	760	751	705	814	761	922
Total Liabilities	1,331	1,169	1,143	1,124	1,132	1,845	1,651
Total Current Liabilities	1,289	215	187	313	138	75	77
Short-Term Debt	978	36	28	128	23	18	18
Accounts Payable	44	50	54	46	16	8.49	6.50
Accrued Expenses	102	59	41	56	68	29	32
Current Deferred Revenue	87	70	64	63	9.25	7.91	9.94
Other Current Liabilities	78	0.60	0.42	20	21	11	10
Total Noncurrent Liabilities	42	954	956	812	994	1,771	1,575
Long-Term Debt	0.00	-	0.05	680	557	527	475
Capital Lease Obligations	0.00	1.06	1.03	37	70	68	65
Other Noncurrent Operating Liabilities	42	953	955	95	368	1,176	1,035
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	73	-409	-392	-419	-319	-1,084	-729
Total Preferred & Common Equity	73	-409	-392	-419	-319	-1,084	-729
Preferred Stock	-	-	-	-	0.00	0.00	0.00
Total Common Equity	73	-409	-392	-419	-319	-1,084	-729
Common Stock	1,739	1,777	1,791	1,806	1,891	1,931	2,740
Retained Earnings	-1,739	-2,185	-2,183	-2,225	-2,210	-3,014	-3,470

This table displays calculated financial ratios and metrics derived from Core Scientific's official financial filings.

Metric	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	904.71%	17.60%	-21.54%	1.65%
EBITDA Growth	0.00%	3,420.42%	-1,320.57%	95.50%	-1,298.35%
EBIT Growth	0.00%	1,893.46%	-1,889.85%	91.31%	-610.67%
NOPAT Growth	0.00%	2,327.02%	-1,597.16%	100.42%	-314.22%
Net Income Growth	0.00%	487.61%	-4,636.52%	88.52%	-433.50%
EPS Growth	0.00%	242.86%	-3,250.00%	89.68%	-575.38%
Operating Cash Flow Growth	0.00%	-138.73%	461.66%	-68.27%	-34.12%
Free Cash Flow Firm Growth	0.00%	0.00%	151.71%	-158.53%	206.23%
Invested Capital Growth	0.00%	14,197,256.16%	-120.49%	142.17%	-361.96%
Revenue Q/Q Growth	0.00%	0.00%	-21.99%	4.29%	-8.52%
EBITDA Q/Q Growth	0.00%	0.00%	-35.42%	77.58%	-15.51%
EBIT Q/Q Growth	0.00%	0.00%	-34.39%	64.30%	-13.68%
NOPAT Q/Q Growth	0.00%	0.00%	-53.83%	101.42%	-178.28%
Net Income Q/Q Growth	0.00%	0.00%	-30.00%	49.25%	-5.61%
EPS Q/Q Growth	0.00%	0.00%	-26.25%	45.38%	19.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	3.14%	-59.15%	-15.55%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-343.69%	-17.43%
Invested Capital Q/Q Growth	0.00%	0.00%	-141.92%	-45.09%	-10.28%
Profitability Metrics	-	-	-	-	-
Gross Margin	17.33%	43.87%	1.31%	24.57%	23.71%
EBITDA Margin	7.87%	27.58%	-286.28%	-16.41%	-225.72%
Operating Margin	-11.67%	24.15%	-329.46%	1.78%	-3.76%
EBIT Margin	-11.88%	21.20%	-322.70%	-35.75%	-249.98%
Profit (Net Income) Margin	-22.52%	8.69%	-335.20%	-49.06%	-257.50%
Tax Burden Percent	100.00%	75.01%	99.21%	100.28%	100.07%
Interest Burden Percent	189.62%	54.64%	104.70%	136.84%	102.94%
Effective Tax Rate	0.00%	24.99%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-30,334.93%	9.52%	-179.19%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-5.42%	-378.53%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-2.69%	-260.48%	0.00%	0.00%
Return on Equity (ROE)	0.00%	6.83%	-439.67%	48.99%	185.59%
Cash Return on Invested Capital (CROIC)	0.00%	-190.48%	0.00%	-333.65%	0.00%
Operating Return on Assets (OROA)	-42,913.33%	9.47%	-127.29%	-23.64%	-110.48%
Return on Assets (ROA)	-81,373.33%	3.88%	-132.22%	-32.44%	-113.81%
Return on Common Equity (ROCE)	0.00%	6.61%	-419.64%	48.99%	185.59%
Return on Equity Simple (ROE_SIMPLE)	0.00%	3.53%	524.33%	41.29%	160.33%
Net Operating Profit after Tax (NOPAT)	-4.43	99	-1,477	6.27	-13
NOPAT Margin	-8.17%	18.11%	-230.62%	1.25%	-2.63%
Net Nonoperating Expense Percent (NNEP)	0.00%	14.94%	199.34%	66.45%	230.95%
Return On Investment Capital (ROIC_SIMPLE)	-	-	396.55%	2.52%	-3.65%
Cost of Revenue to Revenue	93.98%	56.13%	98.69%	75.43%	76.29%
SG&A Expenses to Revenue	26.86%	11.11%	33.31%	18.69%	21.63%
R&D to Revenue	9.73%	1.41%	4.21%	1.43%	2.32%
Operating Expenses to Revenue	29.00%	19.72%	330.77%	22.79%	27.47%
Earnings before Interest and Taxes (EBIT)	-6.44	115	-2,066	-180	-1,277
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.27	150	-1,833	-82	-1,153
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	20,547.95	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	20,547.95	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	5.54	0.00	0.00	0.00	7.68
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	20,547.95	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	5.54	0.00	0.00	0.00	8.37
Enterprise Value to EBITDA (EV/EBITDA)	70.32	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	99.65
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	6.74
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.59	-0.09	-1.42	-1.45
Long-Term Debt to Equity	0.00	0.52	0.00	-1.21	-1.43
Financial Leverage	0.00	0.50	0.69	-0.76	-0.80
Leverage Ratio	1.03	1.76	3.33	-1.51	-1.63
Compound Leverage Factor	1.95	0.96	3.48	-2.07	-1.68
Debt to Total Capital	0.00%	37.14%	-9.93%	339.97%	322.91%
Short-Term Debt to Total Capital	0.00%	4.74%	-9.73%	49.99%	4.43%
Long-Term Debt to Total Capital	0.00%	32.40%	-0.19%	289.98%	318.48%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	2.02%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	60.84%	109.93%	-239.97%	-222.91%
Debt to EBITDA	0.00	5.45	-0.02	-10.26	-1.03
Net Debt to EBITDA	0.00	4.58	0.01	-9.41	-0.30
Long-Term Debt to EBITDA	0.00	4.76	0.00	-8.75	-1.02
Debt to NOPAT	0.00	8.30	-0.03	134.82	-88.42
Net Debt to NOPAT	0.00	6.97	0.01	123.71	-26.13
Long-Term Debt to NOPAT	0.00	7.24	0.00	115.00	-87.21
Altman Z-Score	452,195.72	0.00	0.00	0.00	-4.04
Noncontrolling Interest Sharing Ratio	0.00%	3.21%	4.56%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	2.36	0.46	0.20	6.72
Quick Ratio	0.00	0.37	0.09	0.11	6.22
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-1,974	1,021	-597	635
Operating Cash Flow to CapEx	0.00%	0.00%	53.44%	2,173.36%	45.06%
Free Cash Flow to Firm to Interest Expense	0.00	-246.28	3,556.62	0.00	1,303.17
Operating Cash Flow to Interest Expense	-17.83	-7.08	714.94	0.00	88.08
Operating Cash Flow Less CapEx to Interest Expense	-17.83	-7.08	-622.97	0.00	-107.38
Efficiency Ratios	-	-	-	-	-
Asset Turnover	3,612.87	0.45	0.39	0.66	0.44
Accounts Receivable Turnover	0.00	0.00	660.46	798.73	504.12
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.79	0.89
Accounts Payable Turnover	0.00	0.00	19.37	3.64	4.48
Days Sales Outstanding (DSO)	0.00	0.00	0.55	0.46	0.72
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	18.85	100.36	81.51
Cash Conversion Cycle (CCC)	0.00	0.00	-18.29	-99.91	-80.79
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.01	2,073	-425	179	-469
Invested Capital Turnover	3,711.85	0.53	0.78	-4.09	-3.52
Increase / (Decrease) in Invested Capital	0.00	2,073	-2,497	604	-648
Enterprise Value (EV)	300	0.00	0.00	0.00	4,275
Market Capitalization	300	0.00	0.00	0.00	3,924
Book Value per Share	$0.00	$31.10	($1.09)	($1.55)	($2.94)
Tangible Book Value per Share	$0.00	$6.43	($1.10)	($1.55)	($2.94)
Total Capital	0.01	2,204	-372	249	368
Total Debt	0.00	819	37	846	1,188
Total Long-Term Debt	0.00	714	0.72	721	1,172
Net Debt	0.00	687	-15	776	351
Capital Expenditures (CapEx)	0.00	0.00	384	3.00	95
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.00	409	-118	-337	-51
Debt-free Net Working Capital (DFNWC)	-0.00	541	-65	-267	786
Net Working Capital (NWC)	-0.00	436	-102	-391	769
Net Nonoperating Expense (NNE)	7.78	51	670	253	1,302
Net Nonoperating Obligations (NNO)	0.00	687	-15	776	351
Total Depreciation and Amortization (D&A)	11	35	233	97	124
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	75.12%	-18.38%	-67.03%	-10.04%
Debt-free Net Working Capital to Revenue	0.00%	99.31%	-10.22%	-53.15%	153.85%
Net Working Capital to Revenue	0.00%	80.13%	-15.88%	-77.91%	150.66%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.83)	($6.30)	($0.65)	($4.39)
Adjusted Weighted Average Basic Shares Outstanding	0.00	316.24M	340.65M	379.86M	255.83M
Adjusted Diluted Earnings per Share	$0.00	($0.83)	($6.30)	($0.65)	($4.39)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	316.24M	340.65M	379.86M	255.83M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.83)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	8.50M	373.80M	177.60M	294.12M
Normalized Net Operating Profit after Tax (NOPAT)	-8.55	125	-171	11	-10
Normalized NOPAT Margin	-15.77%	22.96%	-26.74%	2.14%	-2.05%
Pre Tax Income Margin	-22.52%	11.58%	-337.87%	-48.93%	-257.34%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	-4.83	14.40	-7,199.64	0.00	-2,621.33
NOPAT to Interest Expense	-3.32	12.30	-5,145.25	0.00	-27.59
EBIT Less CapEx to Interest Expense	-4.83	14.40	-8,537.55	0.00	-2,816.80
NOPAT Less CapEx to Interest Expense	-3.32	12.30	-6,483.16	0.00	-223.06
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-1.47%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Core Scientific's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	43.69%	-59.82%	-37.33%	-22.60%	-30.55%	17.05%	49.05%	11.18%	-15.54%	-33.50%
EBITDA Growth	-10,126.32%	-414.78%	99.83%	101.49%	95.55%	78.38%	42,747.75%	-6,645.19%	-2,726.82%	-196.78%
EBIT Growth	-10,176.34%	-557.91%	94.81%	98.90%	90.15%	74.57%	1,177.34%	-8,516.31%	-1,041.89%	-139.23%
NOPAT Growth	-8,489.92%	-654.42%	128.45%	100.91%	97.00%	100.62%	936.81%	-30.52%	-242.24%	-1,111.26%
Net Income Growth	-2,514.66%	-818.68%	99.92%	98.86%	90.54%	55.00%	54,401.80%	-8,592.18%	-1,006.45%	-35.69%
EPS Growth	-1,657.14%	-524.00%	100.00%	99.20%	91.06%	50.94%	0.00%	-22,450.00%	-963.64%	198.08%
Operating Cash Flow Growth	-15.35%	5.69%	651.65%	-87.55%	110.44%	-81.29%	11.19%	-93.32%	5.13%	-36.39%
Free Cash Flow Firm Growth	0.00%	0.00%	239.76%	201.41%	167.74%	-129.28%	-122.22%	-92.92%	6.50%	203.21%
Invested Capital Growth	246.47%	-120.49%	-119.44%	-130.95%	-67.81%	142.17%	149.24%	-29.02%	-230.43%	-361.96%
Revenue Q/Q Growth	-0.85%	-25.42%	-0.49%	5.19%	-11.04%	25.71%	26.71%	-21.54%	-32.42%	-1.02%
EBITDA Q/Q Growth	57.51%	-9.91%	99.84%	2,033.22%	-227.31%	-433.62%	424.72%	-396.69%	45.01%	43.98%
EBIT Q/Q Growth	52.14%	-8.98%	95.19%	56.11%	-327.73%	-181.47%	303.90%	-450.99%	43.31%	41.03%
NOPAT Q/Q Growth	61.61%	-58.48%	101.20%	24.56%	-227.19%	132.66%	1,903.52%	-91.65%	-726.52%	3.48%
Net Income Q/Q Growth	46.35%	-0.01%	99.91%	-2,286.60%	-344.34%	-375.61%	207.66%	-482.03%	43.44%	41.67%
EPS Q/Q Growth	50.60%	13.82%	100.00%	0.00%	-450.00%	-372.73%	250.00%	-678.21%	74.06%	143.59%
Operating Cash Flow Q/Q Growth	-135.94%	322.74%	-82.81%	-9.56%	-69.87%	299.39%	2.17%	-94.57%	374.50%	141.64%
Free Cash Flow Firm Q/Q Growth	45.70%	304.90%	32.37%	-31.15%	-63.72%	-188.57%	-0.68%	121.94%	445.71%	-14.16%
Invested Capital Q/Q Growth	-28.83%	-141.92%	-3.94%	0.21%	174.04%	-45.09%	22.41%	-361.48%	25.15%	-10.28%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	-16.65%	-38.96%	26.34%	29.12%	13.66%	27.69%	43.18%	27.51%	-0.16%	5.05%
EBITDA Margin	-203.64%	-300.10%	-0.50%	9.12%	-13.06%	-55.43%	142.05%	-537.15%	-437.06%	-247.38%
Operating Margin	-246.89%	-524.60%	6.30%	7.46%	-10.67%	2.77%	30.71%	4.66%	-43.23%	-42.15%
EBIT Margin	-244.94%	-357.90%	-17.31%	-7.22%	-34.73%	-77.76%	125.13%	-559.78%	-469.55%	-279.75%
Profit (Net Income) Margin	-267.45%	-358.64%	-0.32%	-7.30%	-36.44%	-137.88%	117.16%	-570.44%	-477.44%	-281.35%
Tax Burden Percent	102.51%	95.29%	136.62%	101.41%	100.28%	100.17%	99.90%	100.02%	100.03%	100.14%
Interest Burden Percent	106.51%	105.16%	1.36%	99.61%	104.65%	177.01%	93.72%	101.89%	101.65%	100.43%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-217.36%	-285.33%	2.74%	5.65%	-5.37%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-250.14%	-282.23%	1.71%	2.33%	-9.26%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-639.58%	-194.21%	2.65%	93.18%	45.11%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-856.93%	-479.54%	5.39%	98.83%	39.74%	48.99%	9.74%	112.58%	216.90%	185.59%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	36.61%	-333.65%	-284.87%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-229.65%	-141.18%	-5.68%	-2.96%	-15.86%	-51.41%	89.29%	-426.24%	-322.14%	-123.64%
Return on Assets (ROA)	-250.74%	-141.47%	-0.11%	-2.99%	-16.64%	-91.16%	83.60%	-434.35%	-327.55%	-124.34%
Return on Common Equity (ROCE)	-51.36%	-457.69%	5.39%	98.83%	39.74%	48.99%	9.74%	112.58%	216.90%	185.59%
Return on Equity Simple (ROE_SIMPLE)	-2,260.76%	0.00%	411.12%	224.06%	115.98%	0.00%	11.12%	76.67%	170.71%	0.00%
Net Operating Profit after Tax (NOPAT)	-281	-445	5.32	6.63	-8.43	2.75	55	4.61	-29	-28
NOPAT Margin	-172.82%	-367.22%	4.41%	5.22%	-7.47%	1.94%	30.68%	3.26%	-30.26%	-29.51%
Net Nonoperating Expense Percent (NNEP)	32.79%	-3.10%	1.03%	3.31%	3.88%	52.17%	-61.81%	346.20%	81.31%	42.18%
Return On Investment Capital (ROIC_SIMPLE)	-	119.57%	-	-	-	1.11%	-	-	-	-7.57%
Cost of Revenue to Revenue	116.65%	138.96%	73.66%	70.88%	86.34%	72.31%	56.52%	72.49%	100.16%	95.53%
SG&A Expenses to Revenue	26.66%	32.08%	18.04%	19.22%	20.82%	17.08%	7.86%	18.60%	36.03%	37.83%
R&D to Revenue	3.81%	2.19%	1.17%	1.29%	2.00%	1.32%	1.00%	1.54%	2.98%	5.31%
Operating Expenses to Revenue	230.24%	485.64%	20.04%	21.66%	24.32%	24.92%	12.77%	22.85%	43.06%	46.62%
Earnings before Interest and Taxes (EBIT)	-398	-434	-21	-9.17	-39	-110	225	-790	-448	-264
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-331	-364	-0.60	12	-15	-79	255	-758	-417	-233
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	1.12	2.87	5.49	7.68
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	5.36	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	2.07	3.77	6.03	8.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	6.71	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	17.57	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	29.40	57.71	196.14	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	17.29	42.94	66.28	99.65
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.11	4.38	6.74
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	13.39	-0.09	-0.09	-0.07	-2.02	-1.42	-2.04	-0.57	-0.76	-1.45
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	-1.71	-1.21	-1.97	-0.55	-0.74	-1.43
Financial Leverage	2.56	0.69	1.55	39.93	-4.87	-0.76	-0.69	-0.32	-0.91	-0.80
Leverage Ratio	4.77	3.33	4.82	108.12	-6.10	-1.51	-2.16	-1.02	-1.42	-1.63
Compound Leverage Factor	5.08	3.50	0.07	107.69	-6.39	-2.67	-2.03	-1.04	-1.44	-1.64
Debt to Total Capital	93.05%	-9.93%	-9.86%	-7.91%	198.27%	339.97%	196.06%	-130.06%	-325.26%	322.91%
Short-Term Debt to Total Capital	93.05%	-9.73%	-9.58%	-7.62%	30.11%	49.99%	7.04%	-3.90%	-10.46%	4.43%
Long-Term Debt to Total Capital	0.00%	-0.19%	-0.28%	-0.30%	168.15%	289.98%	189.02%	-126.16%	-314.80%	318.48%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	6.95%	109.93%	109.86%	107.91%	-98.27%	-239.97%	-96.06%	230.06%	425.26%	-222.91%
Debt to EBITDA	-0.72	-0.02	-0.02	-0.04	-2.30	-10.26	3.74	-1.03	-0.56	-1.03
Net Debt to EBITDA	-0.69	0.01	0.02	0.07	-2.12	-9.41	3.09	-0.87	-0.30	-0.30
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-1.95	-8.75	3.61	-1.00	-0.54	-1.02
Debt to NOPAT	-1.02	-0.03	-0.03	-0.04	-1.91	134.82	16.41	16.30	32.50	-88.42
Net Debt to NOPAT	-0.98	0.01	0.02	0.07	-1.77	123.71	13.53	13.72	17.72	-26.13
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-1.62	115.00	15.82	15.81	31.46	-87.21
Altman Z-Score	0.00	0.00	0.00	0.00	0.00	0.00	-1.86	-7.60	-4.89	-1.95
Noncontrolling Interest Sharing Ratio	94.01%	4.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.17	0.46	0.47	0.59	0.43	0.20	1.04	1.58	3.63	6.72
Quick Ratio	0.03	0.09	0.22	0.31	0.14	0.11	0.72	1.35	3.39	6.22
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,002	2,052	2,717	1,870	678	-601	-603	132	723	620
Operating Cash Flow to CapEx	-997.93%	82.71%	1,295.78%	1,900.42%	189.47%	186.48%	69.52%	38.41%	18.33%	47.62%
Free Cash Flow to Firm to Interest Expense	0.00	7,150.46	0.00	0.00	0.00	-561.60	-12,069.80	1,103.41	2,279.39	0.00
Operating Cash Flow to Interest Expense	0.00	404.13	0.00	0.00	0.00	20.28	443.48	10.03	18.02	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-84.46	0.00	0.00	0.00	9.41	-194.40	-16.09	-80.32	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.94	0.39	0.33	0.41	0.46	0.66	0.71	0.76	0.69	0.44
Accounts Receivable Turnover	0.00	660.46	1,659.71	222.52	230.49	798.73	876.10	194.02	151.83	504.12
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.79	0.64	0.57	0.79	0.93	0.99	1.02	0.89
Accounts Payable Turnover	28.14	19.37	18.14	12.60	9.98	3.64	11.78	12.94	15.46	4.48
Days Sales Outstanding (DSO)	0.00	0.55	0.22	1.64	1.58	0.46	0.42	1.88	2.40	0.72
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	12.97	18.85	20.13	28.97	36.57	100.36	30.99	28.22	23.62	81.51
Cash Conversion Cycle (CCC)	-12.97	-18.29	-19.91	-27.33	-34.99	-99.91	-30.57	-26.33	-21.21	-80.79
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,013	-425	-441	-440	326	179	217	-568	-425	-469
Invested Capital Turnover	1.26	0.78	0.62	1.08	0.72	-4.09	-5.01	-1.14	-11.25	-3.52
Increase / (Decrease) in Invested Capital	721	-2,497	-2,711	-1,864	-687	604	659	-128	-751	-648
Enterprise Value (EV)	0.00	0.00	0.00	0.00	0.00	0.00	1,165	2,169	3,367	4,275
Market Capitalization	0.00	0.00	0.00	0.00	0.00	0.00	629	1,653	3,063	3,924
Book Value per Share	$0.20	($1.09)	($1.09)	($1.04)	($1.09)	($1.55)	($1.79)	($6.10)	($2.82)	($2.94)
Tangible Book Value per Share	$0.20	($1.10)	($1.10)	($1.05)	($1.10)	($1.55)	($1.81)	($6.10)	($2.82)	($2.94)
Total Capital	1,051	-372	-372	-364	426	249	332	-471	-172	368
Total Debt	978	37	37	29	845	846	650	613	558	1,188
Total Long-Term Debt	0.00	0.72	1.06	1.08	717	721	627	594	540	1,172
Net Debt	940	-15	-33	-48	781	776	536	516	304	351
Capital Expenditures (CapEx)	5.22	140	1.54	0.95	2.87	12	32	3.14	31	29
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-135	-118	-148	-125	-114	-337	-86	-36	-35	-51
Debt-free Net Working Capital (DFNWC)	-98	-65	-79	-48	-50	-267	29	61	219	786
Net Working Capital (NWC)	-1,075	-102	-115	-76	-178	-391	5.18	43	201	769
Net Nonoperating Expense (NNE)	154	-10	5.71	16	33	198	-156	810	426	238
Net Nonoperating Obligations (NNO)	940	-15	-33	-48	745	776	536	516	304	351
Total Depreciation and Amortization (D&A)	67	70	20	21	24	32	30	32	31	31
Debt-free, Cash-free Net Working Capital to Revenue	-16.50%	-18.38%	-26.07%	-23.57%	-23.57%	-67.03%	-15.27%	-6.20%	-6.18%	-10.04%
Debt-free Net Working Capital to Revenue	-11.92%	-10.22%	-13.88%	-9.12%	-10.30%	-53.15%	5.08%	10.67%	39.28%	153.85%
Net Working Capital to Revenue	-131.01%	-15.88%	-20.15%	-14.34%	-36.94%	-77.91%	0.92%	7.48%	36.07%	150.66%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.23)	($1.06)	($0.03)	($0.02)	($0.11)	($0.52)	$0.91	($4.51)	($1.17)	$0.38
Adjusted Weighted Average Basic Shares Outstanding	354.20M	340.65M	375.42M	375.78M	382.48M	379.86M	230.95M	178.51M	292.49M	255.83M
Adjusted Diluted Earnings per Share	($1.23)	($1.06)	($0.03)	($0.02)	($0.11)	($0.52)	$0.78	($4.51)	($1.17)	$0.51
Adjusted Weighted Average Diluted Shares Outstanding	354.20M	340.65M	375.42M	375.78M	382.48M	379.86M	282.53M	178.51M	292.49M	255.83M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	374.53M	373.80M	376.57M	382.61M	386.02M	177.60M	177.78M	258.22M	279.25M	294.12M
Normalized Net Operating Profit after Tax (NOPAT)	-54	-63	5.32	6.89	-7.97	6.49	59	4.42	-28	-28
Normalized NOPAT Margin	-33.01%	-51.88%	4.41%	5.43%	-7.06%	4.58%	32.80%	3.13%	-29.89%	-29.40%
Pre Tax Income Margin	-260.90%	-376.36%	-0.24%	-7.19%	-36.34%	-137.64%	117.27%	-570.33%	-477.30%	-280.95%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-1,512.05	0.00	0.00	0.00	-103.15	4,500.68	-6,582.14	-1,412.42	0.00
NOPAT to Interest Expense	0.00	-1,551.41	0.00	0.00	0.00	2.57	1,103.46	38.38	-91.02	0.00
EBIT Less CapEx to Interest Expense	0.00	-2,000.63	0.00	0.00	0.00	-114.02	3,862.80	-6,608.27	-1,510.76	0.00
NOPAT Less CapEx to Interest Expense	0.00	-2,040.00	0.00	0.00	0.00	-8.30	465.58	12.25	-189.36	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-1.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Core Scientific's Financials

When does Core Scientific's fiscal year end?

According to the most recent income statement we have on file, Core Scientific's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Core Scientific's net income changed over the last 4 years?

Core Scientific's net income appears to be on an upward trend, with a most recent value of -$1.32 billion in 2024, rising from -$12.21 million in 2020. The previous period was -$246.49 million in 2023.

What is Core Scientific's operating income?

Core Scientific's total operating income in 2024 was -$19.20 million, based on the following breakdown:

Total Gross Profit: $121.07 million
Total Operating Expenses: $140.27 million

How has Core Scientific revenue changed over the last 4 years?

Over the last 4 years, Core Scientific's total revenue changed from $54.19 million in 2020 to $510.67 million in 2024, a change of 842.3%.

How much debt does Core Scientific have?

Core Scientific's total liabilities were at $2.42 billion at the end of 2024, a 84.8% increase from 2023, and a 604,748,650.0% increase since 2020.

How much cash does Core Scientific have?

In the past 4 years, Core Scientific's cash and equivalents has ranged from $0.00 in 2020 to $836.20 million in 2024, and is currently $836.20 million as of their latest financial filing in 2024.

How has Core Scientific's book value per share changed over the last 4 years?

Over the last 4 years, Core Scientific's book value per share changed from 0.00 in 2020 to -2.94 in 2024, a change of -2,937,100.0%.

Related Companies

This page (NASDAQ:CORZZ) was last updated on 4/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Core Scientific (CORZZ) Financials

Frequently Asked Questions About Core Scientific's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Core Scientific (CORZZ) Financials

Annual Income Statements for Core Scientific

Quarterly Income Statements for Core Scientific

Annual Cash Flow Statements for Core Scientific

Quarterly Cash Flow Statements for Core Scientific

Annual Balance Sheets for Core Scientific

Quarterly Balance Sheets for Core Scientific

Annual Metrics and Ratios for Core Scientific

Quarterly Metrics and Ratios for Core Scientific

Frequently Asked Questions About Core Scientific's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools